|   Accel-Rx

David Main becomes new Accel-Rx Chairman of the Board

Vancouver, BC (January 19, 2017) – Accel-Rx, Canada’s national health sciences accelerator, is delighted to announce the appointment of David J. Main as the new Chairman of its Board.  Mr. Main is currently Chairman, President and Chief Executive Officer of Aquinox, and recently completed a three-year term as Chairman of BIOTECanada.


“We are very pleased to welcome David as our new Board Chair,” said Natalie Dakers, President and Chief Executive Officer of Accel-Rx. “An industry veteran with a global perspective, David has grown and lead successful biotech ventures including Inex Pharmaceuticals and now Aquinox. His breadth of experience coupled with his understanding of the Canadian landscape uniquely positions him to help advance Accel-Rx’s role in the health ecosystem.”


“Accel-Rx plays an integral role in the growth of Canada’s health sciences sector,” said Mr. Main, “I look forward to working with the board and the organization as they accelerate the next generation of early-stage companies to drive a globally competitive sector.”


Mr. Main has over 25 years of experience in the health sciences industry. As a co-founder of Aquinox, Mr. Main has overseen the advancement of the Company’s lead product, AQX-1125, from a target validation program to a phase three clinical trial candidate. During this time, he has also been responsible for the transition of Aquinox from a private to a NASDAQ-listed public company having raised over US$300 million in equity.


Mr. Main was formerly the President and CEO of INEX Pharmaceuticals Corp. and, prior to INEX, was Vice President at QLT Inc., one of Canada’s inaugural biotech companies. Mr. Main began his career as a licensed pharmacist at the Royal Columbian Hospital in New Westminster, BC.  He holds a B.Sc. (Pharmacy) and an MBA from the University of British Columbia. Mr. Main formerly served as the Chair of Life Sciences BC (formerly BC Biotech) and BIOTECanada and is currently a Board Director of BIO.org, in addition to serving on a number of other private and not-for-profit Boards.